Dr. Netto’s current research focuses on the evaluation of molecular biomarkers that can serve as potential prognosticators or therapeutic targets in the management of urologic malignancies.
These studies are facilitated by the construction of tissue microarrays coupled with image-analysis technology to be used for immunohistochemistry and FISH analysis of prostatic, bladder, renal and testicular cancers. He also focuses on the molecular diagnostic applications with potential roles in screening and early detection of urologic malignancies.
Ongoing prostate cancer studies are evaluating the role of TMPRSS2-ERG translocation, proliferation markers and mTOR pathway members in predicting prostate cancer progression. The studies are funded by grants from the Prostate Cancer Foundation and the Patrick C. Walsh Foundation, as well as with an NIH/NCI-sponsored Johns Hopkins Prostate SPORE grant.
Studies on urothelial carcinoma involve evaluation of biomarkers in a newly constructed tissue array from a well characterized cohort of cystectomy patients treated at the Brady Urological Institute. Markers being studied include cell-cycle control elements, EGFR expression and mutation analysis, PIK3CA mutation analysis, DNA damage-response elements and mTOR pathway members.
These studies are supported by a 2008 FAMRI Clinical Innovator Award, philanthropic Bladder Fund and NIH/NCI sponsored grants including a PO1 program award.
Additional urologic oncology studies are examining biomarkers of targeted therapies in renal-cell carcinoma, including TOPOIIa, HIF1a/VEGF and mTOR pathway.
- Klock C, Gomes R, João M, Netto G. Prostate Melanosis Associated With Acinar Adenocarcinoma. Int J Surg Pathol. 2010 Oct;18(5):379-80. doi: 10.1177/1066896908329591.
- Albadine R, Wang W, Brownlee NA, Toubaji A, Billis A, Epstein JI, Argani P, Garvin AJ, Couzi R, Schaeffer E, Pavlovich CP, Netto GJ. "Topoisomerase IIA Status in Renal Medullary Carcinoma: Immunoexpression and Gene Copy Alterations of a Potential Target of Therapy. J Urol. 2009 Aug;182(2):735-40. doi: 10.1016/j.juro.2009.03.078.
- K Fujita, CP Pavlovich, G Netto, Y Konishi, WB Isaacs, S Ali, A De Marzo and A Meeker. "Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology." Hum Pathol. 2009 Jul;40(7):924-33. doi: 10.1016/j.humpath.2009.01.004. Epub 2009 Apr 14.
- Lotan TL, Toubaji A, Albadine R, Latour M, Herawi M, Meeker AK, De Marzo AM, Platz EA, Epstein JI, Netto GJ. "TMPRSS2-ERG Gene Fusions are Infrequent in Prostatic Ductal Adenocarcinomas." Modern Pathol. 2009 Mar;22(3):359-65. doi: 10.1038/modpathol.2008.236.
- Cheung WL, Albadine R, Chan T, Sharma R, Netto GJ. "Phosphorylated H2AX in Non-Invasive Low Grade Urothelial Carcinoma of Urinary Bladder: Correlation with Tumor Recurrence." J Urol. 2009 Mar;181(3):1387-92. doi: 10.1016/j.juro.2008.10.146. Epub 2009 Jan 20.
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.Proc Natl Acad Sci U S A. 2013; PMCID: PMC3625331
Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg MP, Bivalacqua T, Allaf ME, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ. TERT Promoter Mutations Occur Early in Urothelial Neoplasia and are Biomarkers of Early Disease and Disease Recurrence in Urine. Cancer Res. 2013; PMCID: PMC3966102
Zheng X, Zhuge J, Bezerra SM, Faraj SF, Munari E, Fallon JT, Yang XJ, Argani P, Netto GJ, Zhong M. High Frequency of TERT mutations in Small Cell Carcinoma of Bladder. J Hematol Oncol. 2014 Jul 20;7:47.PMCID: PMC4223615.
Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC, Chaux A, Epstein JI, Han M, Walsh PC, Partin AW, De Marzo AM, Platz EA, Netto GJ. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol 2011; Nov;24(11):1511-20. PMCID: PMC3360950
Albadine R, Latour M, Toubaji A, Haffner M, Isaacs WB, A Platz E, Meeker AK, Demarzo AM, Epstein JI, Netto GJ. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol 2009; 22(11):1415-22 PMCID: PMC3354529
Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, De Marzo AM, Netto GJ. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 2011; Jul;35(7):1014-20. PMCID: PMC3505676
Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen Y-B,Neilsen ME, Gonzalgo ML, Sidransky D, Schoenberg M, Netto GJ. Expression status and prognostic significance of mTOR pathway members in urothelial carcinoma of urinary bladder following cystectomy. Cancer 2010;116(23):5517-26. PMCID:PMC3568488
Schultz L, Chaux A, Albadine R, Hicks J, Kim JJ, De Marzo AM, Allaf ME, Carducci MA, Rodriguez R, Hammers H, Argani P, Reuter VE, Netto GJ. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol 2011;35(10):1549-56. PMCID: PMC3505672
Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, De Marzo AM, Platz EA, Netto GJ. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol. 2012 Nov;25(11):1543-9. PMCID: PMC4380219
Chaux A, Munari E, Cubilla AL, Hicks J, Lecksell K, Burnett AL, Netto GJ. Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases.Histopathology. 2014;64(6):863-71.PubMed PMID: 24279699.